Shares of pet medicine developer Aratana Therapeutics are soaring in their first trading day on the Nasdaq Global Market.
The stock, ticker symbol PETX, is up 48 percent, or $2.90, to $8.90 per share in afternoon trading, while the Nasdaq exchange climbed less than 1 percent.
The Kansas City, Kan., company raised $34.5 million in an initial public offering of 5.7 million shares that was priced well below the range of $11 to $13 originally expected.
The banks managing the offering may buy an additional 862,500 shares to sell if there's demand. That would increase the IPO proceeds.
Aratana is developing potential pet medicines based on compounds created by human drug companies. It has no approved products on the market, but is developing pain treatments for both cats and dogs.